This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Pancreatic cancer

DNA methyltransferase

In vitro and mouse studies suggest hypomethylating agents could help treat pancreatic ductal adenocarcinoma (PDAC). In a mouse model of aggressive, stroma-rich PDAC, the demethylating agent Dacogen decitabine decreased tumor burden and increased survival compared with vehicle control. Next steps include testing Dacogen plus therapeutic cytokines and immunotherapy.
Astex Pharmaceuticals Inc., Eisai Co. Ltd. and Johnson & Johnson market Dacogen, a DNA methyltransferase inhibitor, to treat acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).

SciBX 6(1); doi:10.1038/scibx.2013.10
Published online Jan. 10, 2013

Patent and licensing status unavailable

Shakya, R. et al. Cancer Res.; published online Nov. 29, 2012;
doi:10.1158/0008-5472.CAN-12-1880
Contact: Benjamin Tycko, Columbia University, New York, N.Y.
e-mail:
bt12@columbia.edu